'Gilead Will Pay Privately Held Ouro's Investors Roughly $1.5B Upfront In Cash And At Least Extra $500M If Certain Clinical Trial Milestones Are Hit; Talks Between Gilead And Ouro Medicines Are At An Advanced Stage And A Deal Could Be Announced In The Coming Days' - Financial Times - Gilead Sciences (NASDAQ:GILD)
Published on March 23, 2026.
The Financial Times reports that Gilead Sciences is in advanced talks with Ouro Medicines, potentially announcing a deal worth $1.5B in cash and potentially an additional $500M if certain Clinical Trial milestones are met. The news comes as a wake-up to the controversy surrounding the company.
Related Articles
BYD's big EV bet is paying off as drivers ditch gas with surging oil prices
BYD's shift to electric vehicles amid surging oil prices is driving significant demand, especially in Asia and China.
Why the oil and gas price shock from the Iran war won’t just fade away
The Iran war has caused a global oil and gas shortage, necessitating extensive market rerouting and storage releases, with limited available supply options.
Venture Global Signs Five-Year Vitol LNG Agreement For 1.5 MTPA - Venture Global (NYSE:VG)
Venture Global signed a multi-million dollar LNG deal with Vitol to expand its supply capabilities, amid mixed market performance and strong investor sentiment.